Ticlopidine

Last updated
Ticlopidine
Ticlopidine.svg
Ticlopidine ball-and-stick.png
Clinical data
Trade names Ticlid
AHFS/Drugs.com Monograph
MedlinePlus a695036
License data
Pregnancy
category
  • AU:B1
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability >80%
Protein binding 98%
Metabolism Liver
Elimination half-life 12 hours (single dose)
4–5 days (repeated dosing)
Excretion Kidney and fecal
Identifiers
  • 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.054.071 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C14H14ClNS
Molar mass 263.78 g·mol−1
3D model (JSmol)
  • Clc1ccccc1CN3Cc2c(scc2)CC3
  • InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2 Yes check.svgY
  • Key:PHWBOXQYWZNQIN-UHFFFAOYSA-N Yes check.svgY
   (verify)

Ticlopidine, sold under the brand name Ticlid, is a medication used to reduce the risk of thrombotic strokes. [1] It is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of neutropenia and thrombotic microangiopathy it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited.

Contents

It was patented in 1973 and approved for medical use in 1978. [5]

Medical uses

Ticlopidine is indicated for the prevention of strokes and when combined with aspirin, for people with a new coronary stent to prevent closure. [1]

Stroke

Ticlopidine is considered a second-line option for the prevention of thrombotic strokes among patients who have previously had a stroke or TIA. Studies have shown that it is superior to aspirin in the prevention of death or future strokes. However, it also has more frequent and serious side effects compared to aspirin, so it is reserved for those patients that cannot take aspirin. [6]

Heart disease

When a patient needs to have a stent placed in one of the vessels around their heart, it is important that that stent stay open to keep blood flowing to the heart. Therefore, patients with stents must take medications after the procedure to help maintain that blood flow. Ticlopidine, taken together with aspirin, is FDA approved for this purpose, and in studies it has been shown to work better than aspirin alone or aspirin with an anticoagulant. [7] [8] However, ticlopidine’s serious side effects make it less useful than its cousin, clopidogrel. [9] Current recommendations no longer recommend ticlopidine’s use. [10]

Contraindications

The use of ticlopidine is contraindicated in anyone with:

Because of the increased risk of bleeding, patients taking ticlopidine should discontinue the medication 10–14 days before surgery. [1]

Adverse effects

The most serious side effects associated with ticlopidine are those that affect the blood cells, although these life-threatening complications are relatively rare. The most common side effects include: [1]

Ticlopidine may also cause an increase in cholesterol, triglycerides, liver enzymes, and bleeding. [1]

Hematological

Use of ticlopidine has been associated with neutropenia, thrombocytopenia, thrombotic microangiopathy (TMA), and aplastic anemia. Because of this risk, patients who are started on ticlopidine are typically monitored with blood tests to test their cell counts every two weeks for the first three months. [1]

Pregnancy and lactation

Ticlopidine is a FDA pregnancy risk category B. There have been no studies done in humans. Studies in rats show that high drug levels could cause toxicity in both mother and fetus, but there are no known birth defects associated with its use. [1]

There have been no studies to test whether ticlopidine goes into breast milk. Studies in rats have shown that it is passed in rats’ milk. [1]

Interactions

Ticlopidine interacts with several classes of medications. It increases the antiplatelet effects of aspirin and other NSAIDs. [1] Taking ticlopidine at the same time as antacids decreases the absorption of ticlopidine. [1] Ticlopidine inhibits liver CYP2C19 [11] and CYP2B6 [12] and thus can affect blood levels of medications metabolized by these systems.

Mechanism of action

Ticlopidine is a tetrahydro-thienopyridine which, when metabolized by the body, irreversibly blocks the P2Y12 component of the ADP receptor on the surface of platelets. Without ADP, fibrinogen does not bind to the platelet surface, preventing platelets from sticking to each other. [1] By interfering with platelet function, ticlopidine prevents clots from forming on the inside of blood vessels. [13] Anti-platelet effects start within 2 days and reach their maximum by 6 days of therapy. Ticlopidine’s effects persist for 3 days after discontinuing ticlopidine although it may take 1–2 weeks for platelet function to return to normal, as the medication affects platelets irreversibly. Therefore, new platelets must be formed before platelet function normalizes. [1]

Pharmacokinetics

Ticlopidine is ingested orally with 80% bioavailability with rapid absorption. Even higher absorption can occur if ticlopidine is taken with food. It is metabolized by the liver with both renal and fecal elimination. Clearance is nonlinear and varies with repeated dosing. After the first dose the half life is 12.6 hours, but with repeated dosing the maximum half life is 4–5 days. Clearance is also slower in the elderly. The drug is 98% reversibly bound to proteins. [1]

Chemical properties

Ticlopidine's systemic name is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine. Its molecular weight is 263.786 g/mol. It is a white crystalline solid. It is soluble in water and methanol and somewhat soluble in methylene chloride, ethanol, and acetone. It self-buffers in water to a pH of 3.6. [1]

History

Ticlopidine was discovered in the 1970s in France by a team led by Fernand Eloy and including Jean-Pierre Maffrand at Castaigne SA that was trying to discover a new anti-inflammatory medication. Pharmacology developers noted that this new compound had strong anti-platelet properties. [14] Castaigne was acquired by Sanofi in 1973. [15] Starting in 1978 the drug was marketed in France under the brand name Ticlid for people at high risk for thrombotic events, who had just come out of heart surgery, were undergoing hemodialysis, had peripheral vascular disease, or who were otherwise at risk for strokes and ischemic heart disease. [14]

Ticlopidine was brought to market in the US by Syntex, which got the drug approved in 1991. [16] Syntex was acquired by the Roche group in 1994. [17] The first generic ticlopidine hydrochloride was FDA approved in 1999. [18] As of April 2015, Roche, Caraco, Sandoz, Par, Major, Apotex, and Teva had discontinued generic ticlopidine and no ticlopidine preparations were available in the US. [19]

Research

Soon after its release, studies regarding ticlopidine found it had the potential to be helpful for other diseases including peripheral vascular disease, [20] diabetic retinopathy, [21] and sickle cell disease. [22] However, none had enough evidence for FDA approval. Due to the blood cell side effects associated with ticlopidine, researchers for treatments for these conditions have turned to other avenues.

Related Research Articles

<span class="mw-page-title-main">Aspirin</span> Medication

Aspirin, also known as acetylsalicylic acid (ASA), is a nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain, fever, and/or inflammation, and as an antithrombotic. Specific inflammatory conditions which aspirin is used to treat include Kawasaki disease, pericarditis, and rheumatic fever.

A transient ischemic attack (TIA), commonly known as a mini-stroke, is a minor stroke whose noticeable symptoms usually end in less than an hour. A TIA causes the same symptoms associated with a stroke, such as weakness or numbness on one side of the body, sudden dimming or loss of vision, difficulty speaking or understanding language, slurred speech, or confusion.

An antiplatelet drug (antiaggregant), also known as a platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that decrease platelet aggregation and inhibit thrombus formation. They are effective in the arterial circulation where classical Vitamin K antagonist anticoagulants have minimal effect.

<span class="mw-page-title-main">Anticoagulant</span> Class of drugs

An anticoagulant, commonly known as a blood thinner, is a chemical substance that prevents or reduces the coagulation of blood, prolonging the clotting time. Some occur naturally in blood-eating animals, such as leeches and mosquitoes, which help keep the bite area unclotted long enough for the animal to obtain blood.

<span class="mw-page-title-main">Clopidogrel</span> Antiplatelet medication

Clopidogrel, sold under the brand name Plavix among others, is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent. It is taken by mouth. Its effect starts about two hours after intake and lasts for five days.

<span class="mw-page-title-main">Coronary thrombosis</span> Medical condition

Coronary thrombosis is defined as the formation of a blood clot inside a blood vessel of the heart. This blood clot may then restrict blood flow within the heart, leading to heart tissue damage, or a myocardial infarction, also known as a heart attack.

<span class="mw-page-title-main">Dipyridamole</span> Anticoagulant drug

Dipyridamole is a nucleoside transport inhibitor and a PDE3 inhibitor medication that inhibits blood clot formation when given chronically and causes blood vessel dilation when given at high doses over a short time.

<span class="mw-page-title-main">Prasugrel</span> Medication used to prevent formation of blood clots

Prasugrel, sold under the brand name Effient in the US, Australia and India, and Efient in the EU) is a medication used to prevent formation of blood clots. It is a platelet inhibitor and an irreversible antagonist of P2Y12 ADP receptors and is of the thienopyridine drug class. It was developed by Daiichi Sankyo Co. and produced by Ube and marketed in the United States in cooperation with Eli Lilly and Company.

<span class="mw-page-title-main">Eptifibatide</span> Antiplatelet drug

Eptifibatide, is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a cyclic heptapeptide derived from a disintegrin protein found in the venom of the southeastern pygmy rattlesnake. It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.

P2Y<sub>12</sub> Protein-coding gene in the species Homo sapiens

P2Y12 is a chemoreceptor for adenosine diphosphate (ADP) that belongs to the Gi class of a group of G protein-coupled (GPCR) purinergic receptors. This P2Y receptor family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. The P2Y12 receptor is involved in platelet aggregation and is thus a biological target for the treatment of thromboembolisms and other clotting disorders. Two transcript variants encoding the same isoform have been identified for this gene.

The history of invasive and interventional cardiology is complex, with multiple groups working independently on similar technologies. Invasive and interventional cardiology is currently closely associated with cardiologists, though the development and most of its early research and procedures were performed by diagnostic and interventional radiologists.

<span class="mw-page-title-main">Coronary stent</span> Medical stent implanted into coronary arteries

A coronary stent is a tube-shaped device placed in the coronary arteries that supply blood to the heart, to keep the arteries open in patients suffering from coronary heart disease. The vast majority of stents used in modern interventional cardiology are drug-eluting stents (DES). They are used in a medical procedure called percutaneous coronary intervention (PCI). Coronary stents are divided into two broad types: drug-eluting and bare metal stents. As of 2023, drug-eluting stents were used in more than 90% of all PCI procedures. Stents reduce angina and have been shown to improve survival and decrease adverse events after a patient has suffered a heart attack—medically termed an acute myocardial infarction.

<span class="mw-page-title-main">Vorapaxar</span> Chemical compound

Vorapaxar is a thrombin receptor antagonist based on the natural product himbacine, discovered by Schering-Plough and developed by Merck & Co.

<span class="mw-page-title-main">Ticagrelor</span> Coronary medication

Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y12 receptor. The drug is produced by AstraZeneca.

<span class="mw-page-title-main">Thienopyridine</span> Class of chemical compounds

Thienopyridines are a class of selective, irreversible ADP receptor/P2Y12 inhibitors used for their anti-platelet activity. They have a significant role in the management of cardiovascular disease.

<span class="mw-page-title-main">Cangrelor</span> Chemical compound

Cangrelor, sold under the brand name Kengreal among others, is a P2Y12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring metabolic conversion.

Adenosine diphosphate (ADP) receptor inhibitors are a drug class of antiplatelet agents, used in the treatment of acute coronary syndrome (ACS) or in preventive treatment for patients who are in risk of thromboembolism, myocardial infarction or a stroke. These drugs antagonize the P2Y12 platelet receptors and therefore prevent the binding of ADP to the P2Y12 receptor. This leads to a decrease in aggregation of platelets, prohibiting thrombus formation. The P2Y12 receptor is a surface bound protein found on blood platelets. They belong to G protein-coupled purinergic receptors (GPCR) and are chemoreceptors for ADP.

<span class="mw-page-title-main">Management of acute coronary syndrome</span>

Management of acute coronary syndrome is targeted against the effects of reduced blood flow to the affected area of the heart muscle, usually because of a blood clot in one of the coronary arteries, the vessels that supply oxygenated blood to the myocardium. This is achieved with urgent hospitalization and medical therapy, including drugs that relieve chest pain and reduce the size of the infarct, and drugs that inhibit clot formation; for a subset of patients invasive measures are also employed. Basic principles of management are the same for all types of acute coronary syndrome. However, some important aspects of treatment depend on the presence or absence of elevation of the ST segment on the electrocardiogram, which classifies cases upon presentation to either ST segment elevation myocardial infarction (STEMI) or non-ST elevation acute coronary syndrome (NST-ACS); the latter includes unstable angina and non-ST elevation myocardial infarction (NSTEMI). Treatment is generally more aggressive for STEMI patients, and reperfusion therapy is more often reserved for them. Long-term therapy is necessary for prevention of recurrent events and complications.

<span class="mw-page-title-main">Regrelor</span> Chemical compound

Regrelor is an experimental antiplatelet drug that was under investigation by Merck Sharp and Dohme in human clinical trials. Although it was initially found to be well tolerated in healthy subjects, safety concerns led to cessation of clinical trials.

<span class="mw-page-title-main">Lysine acetylsalicylate</span> Chemical compound

Lysine acetylsalicylate, also known as aspirin DL-lysine or lysine aspirin, is a more soluble form of acetylsalicylic acid (aspirin). As with aspirin itself, it is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, antithrombotic and antipyretic properties. It is composed of the ammonium form of the amino acid lysine paired with the conjugate base of aspirin.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 "Ticlopidine hydrochloride tablet, film coated". DailyMed. Retrieved 29 August 2021.
  2. "Ticlid (ticlopidine hydrochloride) tablets". DailyMed. Retrieved 29 August 2021.
  3. "Drug Approval Package: Ticlid (Ticlopidine Hydrochloride) NDA #19-979/S-018". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 30 August 2021.
  4. "Active substance: ticlopidine" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 14 January 2021.
  5. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 453. ISBN   9783527607495.
  6. Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B (August 1989). "A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group". The New England Journal of Medicine. 321 (8): 501–507. doi:10.1056/nejm198908243210804. PMID   2761587.
  7. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, et al. (April 1996). "A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents". The New England Journal of Medicine. 334 (17): 1084–1089. doi: 10.1056/nejm199604253341702 . PMID   8598866.
  8. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. (December 1998). "A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators". The New England Journal of Medicine. 339 (23): 1665–1671. doi: 10.1056/nejm199812033392303 . PMID   9834303.
  9. Manolis AS, Tzeis S, Andrikopoulos G, Koulouris S, Melita H (July 2005). "Aspirin and clopidogrel: a sweeping combination in cardiology". Current Medicinal Chemistry - Cardiovascular & Hematological Agents. 3 (3): 203–19. doi:10.2174/1568016054368188. PMID   15974885.
  10. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. (December 2014). "2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. 130 (25): e344–e426. doi: 10.1161/CIR.0000000000000134 . PMID   25249585.
  11. Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, Mansuy D (October 2001). "Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19". Biochemistry. 40 (40): 12112–12122. doi:10.1021/bi010254c. PMID   11580286.
  12. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K (June 2005). "Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation". Clinical Pharmacology and Therapeutics. 77 (6): 553–559. doi:10.1016/j.clpt.2005.02.010. PMID   15961986. S2CID   12520818.
  13. Katzung B, Masters S, Trevor A (2012). Basic and Clinical Pharmacology, 12th ed. pp. Chapter 34: Drugs Used in Disorders of Coagulation.
  14. 1 2 Maffrand JP (2012). "The story of clopidogrel and its predecessor, ticlopidine: Could these major antiplatelet and antithrombotic drugs be discovered and developed today?". Comptes Rendus Chimie. 15 (8): 737–743. doi:10.1016/j.crci.2012.05.006.
  15. Aftalion F (2001). "World War II and the Consequence for World Chemicals". A History of the International Chemical Industry. Chemical Heritage Foundation. p. 296. ISBN   9780941901291.
  16. Flores-Runk P, Raasch RH (September 1993). "Ticlopidine and antiplatelet therapy". The Annals of Pharmacotherapy. 27 (9): 1090–1098. doi:10.1177/106002809302700915. PMID   8219445. S2CID   45299169.
  17. Freudenheim M (3 May 1994). "Roche Set To Acquire Syntex". The New York Times .
  18. "Press release: Apotex First To Market Generic Version Of Ticlid®". July 6, 1999.
  19. "Ticlopidine Tablets". Resolved Shortages Bulletin. American Society of Health-System Pharmacists. April 1, 2015. Retrieved 3 June 2015.
  20. Kirstein P, Jogestrand T, Johnsson H, Olsson AG (August 1980). "Antiaggregatory, physiological and clinical effects of ticlopidine in subjects with peripheral atherosclerosis". Atherosclerosis. 36 (4): 471–480. doi:10.1016/0021-9150(80)90240-3. PMID   7417366.
  21. "Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group". Archives of Ophthalmology. 108 (11): 1577–1583. November 1990. doi:10.1001/archopht.1990.01070130079035. PMID   2244843.
  22. Cabannes R, Lonsdorfer J, Castaigne JP, Ondo A, Plassard A, Zohoun I (1984). "Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises". Agents and Actions. Supplements. 15: 199–212. PMID   6385647.